Marsh Barbel's Anti-Inflammatory Compounds and Blood-Sugar Research

This page covers two claims that do not belong to the plant's core traditional identity the way liver, urinary and reproductive claims do, but that show up repeatedly in its modern laboratory literature: anti-inflammatory activity, and blood-sugar lowering. They are grouped together here because both are, in this plant's case, compound-level pharmacology stories rather than whole-plant traditional-use stories — and because the two claims turn out to be at noticeably different levels of evidentiary strength once read closely. The anti-inflammatory work is real, if modest, animal pharmacology with actual quantified results. The blood-sugar work is thinner than the plant's recent publication count suggests, dominated by two 2026 computational papers, one 2024 study confounded by a second plant, and a compound whose identity carries an unusual caveat worth spelling out in full.

Table of Contents

  1. What Is Actually Being Claimed
  2. Three Real Anti-Inflammatory Studies
  3. Reading the Indomethacin Comparison Correctly
  4. A Compound That Is Not Unique to This Plant
  5. The Blood-Sugar Literature: Thinner Than the Paper Count Suggests
  6. 13-Docosenamide: a Real Number, and a Caution Worth Naming
  7. Why "Published in 2026" Does Not Mean What It Sounds Like Here
  8. A Second Retracted Paper in This Exact Space
  9. Human Evidence: Checked, and Absent
  10. Key Research Papers
  11. Connections

What Is Actually Being Claimed

Two separate pharmacological claims, tested by almost entirely separate sets of papers:

  1. Anti-inflammatory and analgesic activity — the plant, or specific fractions and compounds isolated from it, reduce inflammation and pain in standard rodent assays.
  2. Blood-sugar lowering (antihyperglycaemic / antidiabetic) activity — the plant, or a compound within it, lowers blood glucose or inhibits the enzymes that digest dietary carbohydrate.

Neither claim is part of this plant's classical Ayurvedic identity in the way the diuretic and vrishya claims are — both emerge from twenty-first-century pharmacology screening rather than from named traditional indications, though the 2025 anti-inflammatory paper does note that the plant is traditionally used for "rheumatoid arthritis, kidney infections, jaundice, edema, and gout," several of which have an inflammatory component.

Three Real Anti-Inflammatory Studies

Excluding tangential mentions, three primary studies specifically test anti-inflammatory or analgesic activity for this species, spanning 2016 to 2025:

Hussain and colleagues, 2016 — septic shock model

A terpenoid fraction isolated from the whole plant (70% alcohol extract) was tested in two rat models: carrageenan-induced paw oedema (a standard acute-inflammation assay) and lipopolysaccharide (LPS)-induced septic shock, at oral doses of 100 and 200 mg/kg. In the septic-shock model, the terpenoid fraction significantly normalised markers that LPS challenge had disrupted — lipid peroxidation fell from 7.77 to 4.59 nmol TBARS, nitric oxide fell from 9.72 to 4.15 µmol nitrite per mg of tissue, and superoxide dismutase activity rose from 4.89 to 7.83 units per mg protein, alongside reductions in the inflammatory cytokines IL-1β, IL-6 and TNF-α. Molecular docking analysis in the same paper pointed to TNF-α as the most plausible target for the anti-inflammatory effect.

Bellah and colleagues, 2017 — analgesic activity, with a negative result reported honestly

An ethanol extract of the whole plant was tested for analgesic activity using the acetic-acid writhing test in mice, at 125, 250 and 500 mg/kg, with diclofenac sodium as the reference analgesic. The highest dose produced 58.8% inhibition of writhing — a real, dose-dependent analgesic signal. The same paper also tested antidiarrhoeal activity using a castor-oil-induced model, and reported plainly that this result "was not found to be very promising for further use." That negative finding, reported in the same paper as the positive analgesic one, is worth citing precisely because it shows this research group did not simply report whichever outcome looked best — a rare and welcome instance of a mixed result being stated as a mixed result.

Alghamdi and colleagues, 2025 — an isolated, characterised compound

This is the most rigorous single study in this plant's anti-inflammatory literature. A methanolic extract yielded a single purified compound, stigmast-5-en-3-ol-β-D-glucopyranoside — a beta-sitosterol glucoside, structurally confirmed by infrared, NMR and mass spectrometry, and given the internal code HA-06. In a rat carrageenan-paw-oedema model, HA-06 alleviated inflammation to a degree the paper describes as comparable to indomethacin, a standard nonsteroidal anti-inflammatory reference drug; the unpurified methanolic extract produced similar results. Molecular docking further suggested strong binding affinity for phospholipase A2 (−11.25 kcal/mol) and the glucocorticoid receptor (−11.07 kcal/mol), both plausible anti-inflammatory targets, with molecular dynamics simulation used to check the stability of those docked complexes.

Reading the Indomethacin Comparison Correctly

"Comparable to indomethacin" is the kind of line that gets lifted whole onto a supplement label, and it deserves the same caveat given elsewhere on this site's Benefits pages: a positive-control comparator in an animal assay validates that the assay is capable of detecting an anti-inflammatory effect at all. It does not establish that the tested compound and the reference drug are equally potent in any clinically meaningful sense, and it says nothing about a human dose. "Comparable to indomethacin in a rat paw-oedema assay" is a precise, defensible statement. "As effective as a standard anti-inflammatory drug" is not the same claim, and this page does not make it.

A Compound That Is Not Unique to This Plant

Beta-sitosterol glucosides, as a compound class, occur across a very wide range of unrelated plants and are not distinctive to this species — the parent page already makes the same point about lupeol, this plant's other major triterpene-family constituent. A finding that HA-06 has anti-inflammatory activity in a rat model is a finding about that compound's pharmacology. It becomes evidence specifically for this plant only to the extent this plant is shown to deliver a meaningful, bioavailable amount of it relative to other dietary and botanical sources — a comparison the existing literature does not make.

The Blood-Sugar Literature: Thinner Than the Paper Count Suggests

A search for this plant's four taxonomic names alongside antidiabetic-related terms returns seven records. Read individually, they resolve into a much less unified picture than "seven studies" implies:

Once separated this way, the honest count of real, single-species, whole-plant experimental evidence for a blood-sugar effect is one study, from 2006, never independently replicated in the twenty years since.

13-Docosenamide: a Real Number, and a Caution Worth Naming

The most methodologically interesting recent work is a pair of 2026 papers by Saravanan and Arockiasamy (Cell Biochemistry and Biophysics), both built around network pharmacology and molecular docking of this plant's phytochemistry against Type 2 diabetes-related protein targets (PPAR-γ, LIPE, ADIPOQ, LPL, APOB, and the insulin-signalling and AMPK pathways). Gas chromatography identified 73 distinct phytocompounds in an ethanolic extract, of which 13-docosenamide was the most abundant. The second paper goes beyond computation: the compound was purified to 99.997% by preparative HPLC, structurally confirmed by GC-MS, FTIR and UV-Vis, and tested directly against digestive enzymes, showing 81.34% alpha-glucosidase inhibition at 500 µg/mL (IC₅₀ = 71.41 µg/mL) and moderate alpha-amylase inhibition, with a cytotoxicity IC₅₀ of 445.3 µg/mL in cultured adipocytes — meaning the concentration that starts killing cells in culture is roughly six times higher than the concentration that produces half-maximal enzyme inhibition, a real and reassuring safety margin in this specific assay system.

Two things temper how far this can be read. First, alpha-glucosidase inhibition is not a novel mechanism — it is the mechanism of acarbose, a licensed diabetes drug in wide clinical use, whose effect on blood glucose and HbA1c in real patients is well documented and known to be modest. Any newly identified alpha-glucosidase inhibitor, however promising its in-vitro number looks, is starting from a ceiling that a real drug in this exact mechanistic class has already defined in human trials; it is not competing against an empty field. Second, and more specific to this compound: 13-docosenamide is also widely known outside plant pharmacology as erucamide, a common industrial slip agent added to polyethylene film and other plastics, and the analytical-chemistry literature separately documents it as a frequent background contaminant that migrates from plastic packaging, tubing and laboratory consumables into food and extraction samples. This does not mean the Saravanan and Arockiasamy result is contamination — nothing in either paper suggests a methods problem, and the compound genuinely does occur naturally in many plant seed oils as well. It means that an isolated finding of this specific compound, in a plant extract processed through standard laboratory glassware and plasticware, is exactly the kind of result independent replication exists to confirm before it is treated as this plant's signature antidiabetic constituent. This page states that caution rather than the stronger, unproven claim that the finding is artefactual.

One number this page will not attempt: how much of this plant a person would need to consume to reach a physiologically active concentration of 13-docosenamide. Neither paper reports what fraction of the extract's total weight the compound represents, only that it was "the most abundant" of 73 identified compounds by chromatographic peak — which is a statement about relative abundance, not absolute yield. Without that figure, and without any human pharmacokinetic data for the compound, no dose comparison can be made honestly, so none is offered here.

Why "Published in 2026" Does Not Mean What It Sounds Like Here

Eleven of this plant's 57 total indexed records, across all four names, were published in 2023 or later — a real increase in publication rate that could look, from a search-result count alone, like a plant attracting fresh clinical interest. Reading what those eleven papers actually are tells a different story. Four are green-synthesis nanotechnology papers, using this plant's extract as a chemical reducing agent to manufacture copper or yttrium-oxide nanoparticles, then testing the resulting nanoparticles' antibacterial or toxicological properties — work about a manufacturing process, not about the plant's own traditional benefits. One is a food-packaging materials-science paper using the plant's oil as a component of an antimicrobial film for extending grape shelf life. Two are the computational T2DM papers discussed above. One is the 2024 flower-powder combination study. Two are retraction and Expression-of-Concern notices for the 2021 paper discussed on the Liver and Jaundice page. Only one, a 2025 neuropharmacology paper combining in-vivo behavioural assays with in-silico lead-compound identification, engages with a traditional-use question at all, and even that one is exploratory rather than confirmatory. The genuine takeaway: this plant's recent publication growth is almost entirely in nanomaterials chemistry and computational biology, fields that use it as a convenient, cheap source of plant chemistry to test methods on, not a resurgence of interest in testing its traditional medicinal claims.

A Second Retracted Paper in This Exact Space

As discussed on the Liver and Jaundice page, a 2021 hepato/nephroprotective paper on this plant was retracted in 2025. A second, unrelated paper touching this article's territory was also retracted: Watawana, Jayawardena and colleagues, Application of the Kombucha "tea fungus" for the enhancement of antioxidant and starch hydrolase inhibitory properties of ten herbal teas, Food Chemistry, 2016 — withdrawn the same year it was published. This species (indexed there as Asteracantha longifolia) was one of ten herbal teas fermented with Kombucha culture and then tested for antioxidant capacity and alpha-amylase/alpha-glucosidase inhibitory activity, exactly the enzyme-inhibition territory this article covers. It is not cited as evidence anywhere in this Benefits leg. Between this paper and the liver/kidney paper on the previous page, two of the handful of papers most likely to surface in a general search of this plant's modern pharmacology are retracted — a pattern worth remembering the next time a secondary source cites either one.

Human Evidence: Checked, and Absent

PubMed's own Clinical Trial and Randomised Controlled Trial publication-type filters, queried live across all four taxonomic names, return zero records for any inflammatory, pain-related, or blood-sugar indication. Every finding on this page, without exception, comes from an animal, cell-culture, or computational study.

Back to Table of Contents

Key Research Papers

Every citation below is a PubMed search, never a bare identifier, so a mistyped or stale link cannot silently resolve to the wrong paper.

  1. Hussain MS, Azam F, Ahamed KF, Ravichandiran V, Alkskas I. Anti-endotoxin effects of terpenoids fraction from Hygrophila auriculata in lipopolysaccharide-induced septic shock in rats. Pharmaceutical Biology, 2016. Find on PubMed.
  2. Bellah SM, Islam MN, Karim MR, Rahaman MM, and colleagues. Evaluation of cytotoxic, analgesic, antidiarrheal and phytochemical properties of Hygrophila spinosa (T. Anders) whole plant. Journal of Basic and Clinical Physiology and Pharmacology, 2017. Reports both a positive analgesic finding and an explicitly negative antidiarrhoeal one. Find on PubMed.
  3. Alghamdi MA, Azam F, Sarfaraj Hussain M, Ali MAM, and colleagues. Isolation, characterization, and anti-inflammatory effects of β-sitosterol-β-D-glucoside from Hygrophila auriculata: experimental validation, molecular docking, and molecular dynamics simulations. Chemistry & Biodiversity, 2025. Find on PubMed.
  4. Vijayakumar M, Govindarajan R, Rao GM, Rao ChV, and colleagues. Action of Hygrophila auriculata against streptozotocin-induced oxidative stress. Journal of Ethnopharmacology, 2006. The one genuine single-species diabetes-model study in this literature. Find on PubMed.
  5. Almutairi FM. Antihyperglycemic potential of dried powder combination of Hygrophila auriculata and Cordia macleodii: in vivo study in Sprague Dawley rats. Journal of Pharmacy and Bioallied Sciences, 2024. A flower-powder, two-plant combination study — read the methods before attributing the result to either plant alone. Find on PubMed.
  6. Saravanan S, Arockiasamy E. Networking pharmacology and integrated bioinformatic analysis of Hygrophila auriculata for lipid metabolism modulation in type 2 diabetes mellitus. Cell Biochemistry and Biophysics, 2026. Computational only. Find on PubMed.
  7. Saravanan S, Arockiasamy E. Systems-level analysis of 13-docosenamide reveals its regulatory role on PPAR, AMPK, and insulin pathways in T2DM: in vitro and in silico approaches. Cell Biochemistry and Biophysics, 2026. Real in-vitro alpha-glucosidase inhibition data for an isolated, purified compound. Find on PubMed.
  8. Retracted — do not cite. Watawana MI, Jayawardena N, Choo C, Waisundara VY. Application of the Kombucha "tea fungus" for the enhancement of antioxidant and starch hydrolase inhibitory properties of ten herbal teas. Food Chemistry, 2016; retracted 2016. Included only so the retraction is verifiable and recognisable. Verify on PubMed.
  9. General, not species-specific. Acarbose and alpha-glucosidase inhibitor clinical trial effects on HbA1c — the established ceiling for this mechanism class. Search PubMed.
  10. General, not species-specific. Erucamide (13-docosenamide) as a plastic additive and a documented migration and background-contamination compound in food-contact and analytical chemistry. Search PubMed.

Live PubMed Searches

Back to Table of Contents

Connections

Back to Table of Contents